+

WO2000074667A3 - Methodes et compositions destinees a la modulation de l'action de medicaments par deterioration de telomeres - Google Patents

Methodes et compositions destinees a la modulation de l'action de medicaments par deterioration de telomeres Download PDF

Info

Publication number
WO2000074667A3
WO2000074667A3 PCT/US2000/015544 US0015544W WO0074667A3 WO 2000074667 A3 WO2000074667 A3 WO 2000074667A3 US 0015544 W US0015544 W US 0015544W WO 0074667 A3 WO0074667 A3 WO 0074667A3
Authority
WO
WIPO (PCT)
Prior art keywords
activity
telomere damage
taxane
compositions
telomerase inhibitor
Prior art date
Application number
PCT/US2000/015544
Other languages
English (en)
Other versions
WO2000074667A2 (fr
Inventor
Jessie L-S Au
Guillaume Wientjes
Original Assignee
Jessie L-S Au
Guillaume Wientjes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jessie L-S Au, Guillaume Wientjes filed Critical Jessie L-S Au
Priority to AU54665/00A priority Critical patent/AU5466500A/en
Publication of WO2000074667A2 publication Critical patent/WO2000074667A2/fr
Publication of WO2000074667A3 publication Critical patent/WO2000074667A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

L'invention concerne des méthodes et des compositions permettant de moduler l'activité d'agents thérapeutiques destinés au traitement d'un cancer, consistant à administrer au moins un agent qui (seul ou combiné) induit la détérioration des télomères et inhibe l'action de la télomérase dans la cellule cancéreuse. Cette méthode utilise, au départ, un agent d'induction de détérioration de télomères, tel que le paclitaxel, et un agent d'inhibition de la télomérase tel qu'AZT. Cette invention a également trait à des méthodes d'identification d'autres agents dotés d'une action d'induction de la détérioration des télomères et/ou d'une action d'inhibition de la télomérase (ainsi que des compositions possédant une telle action), utilisés dans le traitement du cancer.
PCT/US2000/015544 1999-06-04 2000-06-05 Methodes et compositions destinees a la modulation de l'action de medicaments par deterioration de telomeres WO2000074667A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU54665/00A AU5466500A (en) 1999-06-04 2000-06-05 Methods and compositions for modulating drug activity through telomere damage

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13754999P 1999-06-04 1999-06-04
US60/137,549 1999-06-04

Publications (2)

Publication Number Publication Date
WO2000074667A2 WO2000074667A2 (fr) 2000-12-14
WO2000074667A3 true WO2000074667A3 (fr) 2003-07-03

Family

ID=22477930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/015544 WO2000074667A2 (fr) 1999-06-04 2000-06-05 Methodes et compositions destinees a la modulation de l'action de medicaments par deterioration de telomeres

Country Status (2)

Country Link
AU (1) AU5466500A (fr)
WO (1) WO2000074667A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087286A2 (fr) * 2000-05-17 2001-11-22 Avi Biopharma, Inc. Inhibiteurs d'enzymes antisens permettant une redirection metabolique
US7439271B2 (en) * 2001-06-27 2008-10-21 The Gillette Company Reduction of hair growth
AU2006239677A1 (en) * 2005-04-25 2006-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001835A1 (fr) * 1994-07-07 1996-01-25 Geron Corporation Telomerase mammifere
WO1996041016A1 (fr) * 1995-06-07 1996-12-19 Geron Corporation Procedes de mesure de la longueur d'un telomere
WO1997038013A1 (fr) * 1996-04-09 1997-10-16 The University Of Texas System Modulation de la telomerase mammalienne par des acides nucleiques peptidiques
WO1999009212A1 (fr) * 1997-08-18 1999-02-25 Queen Mary & Westfield College Test de telomerase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001835A1 (fr) * 1994-07-07 1996-01-25 Geron Corporation Telomerase mammifere
WO1996041016A1 (fr) * 1995-06-07 1996-12-19 Geron Corporation Procedes de mesure de la longueur d'un telomere
WO1997038013A1 (fr) * 1996-04-09 1997-10-16 The University Of Texas System Modulation de la telomerase mammalienne par des acides nucleiques peptidiques
US6046307A (en) * 1996-04-09 2000-04-04 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
WO1999009212A1 (fr) * 1997-08-18 1999-02-25 Queen Mary & Westfield College Test de telomerase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUMINIECKI L.: "Telomerase as therapeutic target", ACTA BIOCHIMICA POLONICA, vol. 43, no. 3, 1996, pages 531 - 538, XP000972359 *
KONDO YASUKO ET AL: "Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis", ONCOGENE,GB,BASINGSTOKE, HANTS, vol. 16, no. 17, 30 April 1998 (1998-04-30), pages 2243 - 2248, XP000864718, ISSN: 0950-9232 *
NEIDLE S. ET AL: "Commentary: Telomerase as an anti-cancer target. Current status and future prospects", ANTI CANCER DRUG DESIGN, vol. 14, 1999, pages 341 - 347, XP000972301 *

Also Published As

Publication number Publication date
AU5466500A (en) 2000-12-28
WO2000074667A2 (fr) 2000-12-14

Similar Documents

Publication Publication Date Title
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
WO2004030627A3 (fr) Methodes et compositions synergetiques pour le traitement du cancer
MXPA04006039A (es) Metodo para el tratamiento de afecciones vasculares y neuronales perifericas.
EP1401479A4 (fr) Detection et therapie de plaques vulnerables a l'aide de composes photodynamiques
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
WO2002072031A3 (fr) Composes de tetracycline substitue utilises en tant qu'antifongiques synergiques
WO2006091395A3 (fr) Inhibiteurs d'activite d'akt
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
WO2000038665A3 (fr) Techniques permettant d'utiliser un antagoniste de l'integrine et un ou plusieurs agents antineoplasiques comme therapie combinee pour traiter les maladies neoplasiques
MXPA03010085A (es) Composiciones y su uso en la hiperplasia.
WO2006135627A3 (fr) Inhibiteurs de l'activite akt
MY133996A (en) Compounds for the treatment of ischemia
WO2006110638A3 (fr) Inhibiteur de l'activite akt
WO2001078783A3 (fr) Compositions renfermant des agents naturels destinees au traitement du cancer
WO2001017543A3 (fr) Compositions et procedes permettant la prevention ou le traitement du cancer et de la perte osseuse associee au cancer
BR0011225A (pt) Agente para tratar de olhos secos, seu método e uso
WO2002036129A3 (fr) Traitement topique de la mastalgie
WO2005060960A3 (fr) Utilisation de l'histamine pour le traitement de maladies osseuses
WO2001015677A3 (fr) Utilisation d'agonistes de 5-ht1b/1d pour le traitement des douleurs oculaires
WO2003012051A8 (fr) Inhibiteur de methylation d'adn
TNSN07203A1 (en) Pharmaceutical compositions for the treatment of cellulite
WO2004093856A3 (fr) Combinaison d'un inhibiteur de cox-2 et d'un agent antineoplastique de type d'alkylation destinee au traitement de la neoplasie
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2002041831A3 (fr) Derives d'inositol augmentant la secretion de chrolure et freinant l'inflammation
WO2000074667A3 (fr) Methodes et compositions destinees a la modulation de l'action de medicaments par deterioration de telomeres

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载